Genfit will participate in the H.C. Wainwright conference in New York on September 15
The biopharmaceutical company based in Loos will participate in an American investor meeting dedicated to life sciences stocks. An opportunity for its management to present its positioning to the international financial community.
A presentation scheduled for September 15 in New York
Genfit announced on September 10, 2026 that its management would participate in the 28th edition of the H.C. Wainwright Global Investment Conference.
The event will be held in New York on September 15, 2026 at 11:00 a.m. (Eastern Time), in the form of a presentation and individual meetings with investors.
A replay of the presentation will be accessible via the "Events and Presentations" page in the investor relations section of the company's website.
A portfolio focused on rare liver diseases
Genfit presents itself as a biopharmaceutical company dedicated to patients with rare and potentially life-threatening liver diseases.
The company focuses its efforts on acute-on-chronic liver failure (ACLF) and associated conditions, and targets other serious pathologies such as cholangiocarcinoma, urea cycle disorders and organic acidurias.
Its portfolio also includes a diagnostic franchise with NIS2+ for the detection of MASH. In 2024, elafibranor (Iqirvo) received accelerated approval from the FDA, EMA and MHRA for second-line treatment of primary biliary cholangitis.
